Pegylated liposomal doxorubicin for platinum-resistant or refractory Müllerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of Fallopian tube and peritoneal carcinoma): A single-institutional experience

Fukuda,Takeshi; Sumi,Toshiyuki; Teramae,Masatomo; Nakano,Yusuke; Morishita,Masanari; Terada,Hiroyuki; Yoshida,Hiroyuki; Matsumoto,Yoshinari; Yasui,Tomoyo; Ishiko,Osamu

doi:10.3892/ol.2012.971

Pegylated liposomal doxorubicin for platinum-resistant or refractory Müllerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of Fallopian tube and peritoneal carcinoma): A single-institutional experience

Authors:
- Takeshi Fukuda
- Toshiyuki Sumi
- Masatomo Teramae
- Yusuke Nakano
- Masanari Morishita
- Hiroyuki Terada
- Hiroyuki Yoshida
- Yoshinari Matsumoto
- Tomoyo Yasui
- Osamu Ishiko
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine, Abeno-ku, Osaka 545-8585, Japan
Published online on: October 16, 2012 https://doi.org/10.3892/ol.2012.971
Pages: 35-38

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) in patients with Müllerian carcinoma treated at our hospital. Nineteen patients with platinum-resistant Müllerian carcinoma were treated with intravenous PLD 50 mg/m2 every 4 weeks. Tumor response was assessed by MRI following every 2-3 cycles of treatment. The severity of adverse events was assessed according to the Common Terminology Criteria for Adverse Events (v3.0). The best overall responses in the 19 patients were identified as 5 partial responses (PR), 6 stable diseases (SD) and 8 progressive diseases (PD). Response rate was 26.3%. The proportion of patients with CR, PR or SD was 57.9%. The median time to progression was 188.0 days. The median survival time was 381.0 days. Toxicity grades were identified as one grade III hand-foot syndrome, two grade III neutropenia, one grade IV hand-foot syndrome, one grade IV stomatitis and one grade IV neutropenia. The present study confirmed that PLD is an effective drug when administered as a salvage therapy for the treatment of Müllerian carcinoma and is associated with a reduced toxicity profile compared with current therapeutic options.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar
2	Seewaldt VL, Greer BE, Cain JM, et al: Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial. Am J Obstet Gynecol. 170:1666–1670. 1994. View Article : Google Scholar : PubMed/NCBI
3	Neijt IP, ten Bokkel Huiniuk WW, van der Berg ME, et al: Long-term survival in ovarian cancer. Mature data from the Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer. 27:1367–1372. 1991.PubMed/NCBI
4	Dear RF, Gao B and Harnett P: Recurrent ovarian cancer: Treat ment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre Experience. Asia Pac J Clin Oncol. 6:66–73. 2010. View Article : Google Scholar : PubMed/NCBI
5	Safra T, Groshen S, Jeffers S, Tsao-Wei DD, Zhou L, Muderspach L, Roman L, Morrow CP, Burnett A and Muggia FM: Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome. Cancer. 91:90–100. 2001. View Article : Google Scholar : PubMed/NCBI
6	No authors listed. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta Analysis Project. J Clin Oncol. 9:1668–1674. 1991.PubMed/NCBI
7	A’Hern RP and Gore ME: Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol. 13:726–732. 1995.PubMed/NCBI
8	Fanning J, Bennett TZ and Hilgers RD: Meta-analysis of cisplatin, doxorubicin and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. Obstet Gynecol. 80:954–960. 1992.PubMed/NCBI
9	Singal PK and Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med. 339:900–905. 1998. View Article : Google Scholar : PubMed/NCBI
10	Gabizon A and Martin F: Polyethylene glycol-coated (pegylated) liposomal doxorubicin: rationale for use in solid tumors. Drugs. 54(Suppl 4): 15–21. 1997.PubMed/NCBI
11	Collins Y and Lele S: Long-term pegylated liposomal doxorubicin use in recurrent ovarian carcinoma. J Natl Med Assoc. 97:1414–1416. 2005.PubMed/NCBI
12	Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:4571958. View Article : Google Scholar
13	Ferrandina G, Corrado G, Licameli A, Lorusso D, Fuoco G, Pisconti S and Scambia G: Pegylated liposomal doxorubicin in the management of ovarian cancer. Ther Clin Risk Manag. 6:463–483. 2010.PubMed/NCBI
14	Gladieff L, Ferrero A, De Rauglaudre G, et al: Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Ann Oncol. 5:1185–1189. 2011.
15	Kurtz JE, Kaminsky MC, Floquet A, et al: Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCGI) CALYPSO sub-study. Ann Oncol. 22:2417–2423. 2011. View Article : Google Scholar
16	Gordon AN, Granai CO, Rose PG, et al: Phase II study of stealth liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol. 18:3093–3100. 2000.
17	Johnston SRD and Gore ME: Caelyx: phase II studies in ovarian cancer. Eur J Cancer. 37(Suppl 9): S8–S14. 2001.
18	Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME and Lacave AJ: Recurrent epithelial ovarian carcinoma: a randomized phase II study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 19:3312–3322. 2001.PubMed/NCBI
19	Katsumata N, Fujiwara Y, Kamura T, et al: Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with Müllerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: A phase II study of the Japanese Gynecologic Oncology Group. Jpn J Clin Oncol. 38:777–785. 2008.PubMed/NCBI
20	Muggia FM, Hainsworth JD, Jeffers S, et al: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol. 15:987–993. 1997.PubMed/NCBI
21	Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore M, Lacave AJ and Mutch D: Interim analysis of a phase III randomized trial of doxil/caelyx (D) versus topotecan (T) in the treatment of patients with relapsed ovarian cancer. Proc Am Soc Clin Oncol. 9:3802000.